Kras inhibitors

A compound of the formula:

• wherein:
• A is —C(H)— or —N—;
• B is —C(R4)— or —N—;
• R1 is a group of the formula
• R1b is H or C1-3 alkyl;
• R1d is C1-3 alkyl, C1-3 haloalkyl or C3-4 cycloalkyl;
• R1e is C1-3 alkylene;
• Ring A1 and Ring A2 are C3-4 cycloalkyl or a 3- or 4-membered heterocycle containing a heteroatom selected from N, O, and S;
• X1 and X2 are —CH— or —N—;
• X3 is —CH2— or —O—;
• X4 and X5 are each independently C1-3 alkyl, halogen, or H;
• m, m′, s, t, u, v, and w are each 0 or 1;
• R2 is halogen or C1-3 alkyl;
• Z1 is —C(CN)— or —N—;
• Z2 is —C(R3c)— or —N—;
• Z3 is —O— or —S—;
• R3a, R3b, and R3c are each independently H, halogen, or C1-3 alkyl;
• R4 is H, C1-3 alkyl, C1-3 alkoxy optionally substituted with 1, 2, 3, or 4 substituents independently selected from hydroxyl and methyl, or
• R4 is a group of the formula
• (i)
• wherein
• R4b is H or methyl;
• and
• R4c and R4d are each independently C1-3 alkyl, hydroxyl, or C1-3 haloalkyl;
• or
• R4c and R4d together with the nitrogen or carbon atom to which they are attached form a 4-, 5-, or 6-membered heterocycle;
• or
• (ii)
• wherein
• R5a is halogen, hydroxy, C1-3 alkyl, C1-3 alkoxy, or C1-3 alkoxy-C1-3 alkyl;
• R5d is C1-3 alkyl;
• R5e and R5f together with the carbon atom to which they are attached form a
• 4-, 5-, or 6-membered heterocycle;
• R5e and R5c are each independently H, C1-6 alkyl optionally substituted with one or more deuterium, C3-5 cycloalkyl optionally substituted with halogen or C1-3 haloalkyl, or 3-, 4-, or 5-membered heterocycle containing a heteroatom selected from N, O, and S;
• or
• R5b and R5c together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, or 6-membered heterocycle or a 6-, 7-, or 8-membered spiro heterocycle, wherein each heterocycle or spiro heterocycle optionally contains a further heteroatom selected from N, O, and S, and wherein the heterocycle and the spiro heterocycle is each optionally substituted with one or more halogen, deuterium, C1-3 alkyl, or C1-3 haloalkyl;
• or
• R5a and R5b together with the atoms to which they are attached form a 4-, 5-, or 6-membered heterocyclic fused ring optionally containing a further heteroatom selected from N, O, and S, R5c is C1-3 alkyl, and the 4-, 5-, or 6-membered fused ring is optionally further substituted with a C1-3 alkyl;
• and
• p and r are each 0, 1, or 2;
• (iii)
• wherein
• R6 is selected from halogen, hydroxy, C1-3 alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, and C1-3 dialkylamino;
• and
• n is 0 or 1;
• and
• (iv)
• wherein
• R7 is a C1-3 alkyl;
• and
• R7a is a 4-, 5-, or 6-membered heterocycle optionally containing a further heteroatom selected from N, O, and S;
• or
• R7 and R7a together with the atoms to which they are attached form a 4-, 5-, or 6-membered heterocyclic ring optionally containing a further heteroatom selected from N, O, and S;
• or a pharmaceutically acceptable salt thereof.